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Abstract: I n t r o d u c t i o n: Peripheral arterial occlusive disease (PAOD) is a disease with worldwide 
increasing occurrence. Diabetic patients are greatly exposed on the risk of PAOD and its complications. 
Th e aim of the study was to check the infl uence of preoperative HbA1C on the outcomes of patients with 
diabetes undergoing PAOD related endovascular treatment.
M a t e r i a l  a n d  M e t h o d s: Th e study was conducted among 59 patients with PAOD referred from 
the diabetic foot outpatient for endovascular treatment. Th ey were included in one-year observation based 
on follow-up visits in 1, 3, 6 and 12 months aft er angioplasty and divided into 2 groups basing on their 
preoperative glycaemia. Th e clinical condition of the lower limbs was assessed by use of the Rutherford 
classifi cation, ankle-brachial index (ABI) and toe-brachial index (TBI). Changes in patients’ quality of 
life (QoL) were also evaluated.
R e s u l t s: Reintervention within 12 months were less frequent in patients with HbA1C ≤8.0% than in 
HbA1C >8.0% patients (9.09% vs. 35.48%, p = 0.03). TBI of the treated limb was lower in patients with 
elevated than in patients with proper glycaemia at 6 month [0.2 (0.0–0.38) vs. 0.38 (0.31–0.46); p <0.008] 
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and 12 month follow-up [0.17 (0.0–0.27) vs. 0.32 (0.25–0.38); p <0,001]. Th e rate of healed ulcerations 
aft er 6 months was higher in patients HbA1C ≤8.0% (45.0% vs. 16.13%; p = 0.02) and they had signifi cantly 
greater improvement of QoL.
C o n c l u s i o n: Results of this study shows that preoperative level of glycaemia is an important factor 
for long-term prognosis in diabetic patients with PAOD. Elevated HbA1C level decreases signifi cantly 
long-term improvement of QoL in DM patients undergoing endovascular treatment.
Key words: peripheral arterial occlusive disease, diabetes mellitus, HbA1C, quality of life, endovascular 
treatment.
Introduction
Atherosclerosis with all its complications is one of the most urgent issues in present-
day medicine, especially in well-developed countries, and it still remains the leading 
cause of deaths and disabilities among adults [1, 2]. One of its manifestations 
is peripheral arterial occlusive disease (PAOD) which occurrence is increasing 
worldwide  [3]. Th ere are multiple PAOD co-factors such as diabetes mellitus 
(DM), hypertension, hypercholesterolemia, obesity, nicotinism or chronic kidney 
disease [3 – 8]. Diabetic patients are one of the most exposed on the risk of PAOD and 
its complications including incidence as well as its severity [6].
It is believed that 4–10% of patients with diagnosed DM may develop diabetic foot 
ulcer and their lifetime risk can reach up to 25% [9]. Amputation relative risk among 
patients with diabetic foot is up to 23.3 times compared to atherosclerotic patients 
without DM, causing mortality up to 50% depending on studied population and 
their location [10, 11]. Atherosclerotic lesions can be located in aorto-iliac, femoro-
popliteal and below-the knee arteries [12]. In DM patients, great number of the 
lesions are located in the below the knee arteries (tibial posterior and anterior arteries, 
fi bular and foot arteries) causing the critical limb ischaemia, which oft en requires 
endovascular treatment (Percutaneous Transluminal Angioplasty — PTA)  [13]. Th e 
co-incidence of peripheral arteries disease and DM is also the cause of increase rate 
of complications such as MACE’s and restenosis [14].
In modern vascular medicine, great attention is paid to searching for laboratory 
parameters that can predict future outcomes of patients undergoing endovascular 
treatment. [15, 16] Th e aim of this study was to check the infl uence of preoperative 
HbA1C level on the outcomes of DM patients undergoing PTA due to PAOD.
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Materials and Methods
Patients
Th e study, which was a prospective analysis of endovascular procedures registry, 
was conducted among DM patients administered from diabetic-foot outpatient to 
Angiology Department for endovascular treatment. Th ose of them, who were currently 
undergoing insulin therapy and diagnosed with critical limbs ischemia, were included 
in this analysis. Basing on the preoperative level of HbA1C patients were dividing 
into two groups: with HbA1C level ≤8.0% and with HbA1C level >8.0%  [17]. Data 
concerning immediate and distant outcomes of PTA were obtained during one-year 
observation based on follow-up visits in 1, 3, 6 and 12 months aft er PTA. Th e clinical 
condition of the lower limbs was assessed using the Rutherford classifi cation, Doppler 
ultrasound, ankle-brachial index (ABI) and toe-brachial index (TBI). Th e data on 
Major Adverse Cardiovascular Events was also analysed.
PAOD Diagnostics
PAOD was diagnosed in the angio-CT scan or Doppler ultrasound and confi rmed in 
an angiographic study.
Endovascular Procedures and pharmacology
In all patients, PTA of lower limbs arteries was performed using standard procedures 
and equipment. During the one-year follow-up, every patient was taking insulin, 
statins and one or two antiplatelet drugs depending on the stent implantation and 
type.
Quality of life assessment
Patients recruited to the study were subjected to evaluation of their quality of life 
(QoL) based on two questionnaires: generic EuroQol-5D (EQ5D-3L) and disease 
specifi c Vascular Quality of Life Questionnaire (VascuQol-25). EQ5D contains Visual 
Analog Scale for general health conditions assessment (higher result represents better 
QoL) and 5 questions representing domains (if lower result the better QoL): mobility, 
self-care, daily activities, pain/discomfort and anxiety/depression. VascuQol consist 
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of 25 questions divided into 5 subscales (higher result represents better QoL): pain, 
symptoms, activities, social well-being and emotional well-being. Patients were asked 
to fulfi l the questionnaires before the procedure as well as during the follow-up visits.
Endpoints
During all follow-up visits, the clinical condition in the Rutherford scale, need of 
reintervention due to restenosis or arterial reocclusion and MACE (including death 
from cardiovascular causes, stroke, myocardial infarction, limb amputation) were 
evaluated.
Statistical Analysis
Th e analysis was performed using Statistica soft ware, version 13.0. Th e results were 
presented basing on the parameters of descriptive statistics including proportions, 
mean values and standard deviations, or median values and the corresponding 
quartiles, as appropriate. In order to confi rm a normal distribution, the Shapiro-Wilk 
test was used. To verify homogeneity of variance the Levene’s test was performed. 
T-student test for homogeneous variances was used to compare nominal variables 
with continuous variables, which were normally distributed. Th e comparison of TBI 
values between patients with diff erent levels of HbA1C was performed with the use of 
Mann Whitney U test. Chi-square and Fisher’s exact tests were applied to compare 
the categorical variables between the analyzed groups. Th e signifi cance level was set 
at 0.05.
Results
In this study 59 patients (18 women and 41 men) were analyzed. Th eir detailed 
characteristics were included in Table 1.
Patients with HbA1C level >8.0% had significantly more restenosis causing 
reinterventions during 1-year observation compared to those with HbA1C ≤8.0% 
(35.48% vs. 9.09%, p = 0.03). Th e rate of healed ulcerations aft er 6 months was lower 
in patients with HbA1C >8.0% (16.13% vs. 45.0%; p = 0.02), however this phenomena 
was not statistically signifi cant aft er 1 year (54.84% vs. 61.9%; p = 0.61). Th ere weren’t 
signifi cant diff erences in 12-month MACEs (17.14% vs. 16.67%), death (14.29% vs. 
8.33%) or amputation rate (19.35% vs. 13.64%) between those groups.
 Impact of pre-operative glycated haemoglobin A1C level on 1-year outcomes… 53
Table 1. Group characteristics.
Number of patients ALLn = 59 (100%)
HbA1C >8.0
n = 35 (59.32%)
HbA1C ≤8.0
n = 24 (40.68%) P value
Male [n (%)] 41 (69.49%) 25 (71.43%) 16 (66.67%) NS
Age [years (±SD)] 68.50 ± 9.579 68.40 ± 9.80 68.65 ± 9.45 NS
Rutherford Scale
[n (%)]
4 6 (10.17%) 2 (5.72%) 4 (16.67%)
NS5 29 (49.15%) 20 (57.14%) 9 (37.50%)
6 24 (40.68%) 13 (37.14%) 11 (45.83%)
Level of lesion
[n (%)]
Aorto-Iliac 3 (5.08%) 1 (2.86%) 2 (8.33%)
0.042Fem-Pop 14 (23.73%) 6 (17.14%) 8 (33.33%)
BTK 32 (54.24%) 22 (62.86%) 10 (41.67%)
Multi-level 10 (16.95%) 6 (17.14%) 4 (16.67%)
Coronary artery disease 28 (47.46%) 19 (54.29%) 9 (37.5%) 0.039
History of myocardial infarction 15 (25.42%) 10 (28.57%) 5 (20.83%) NS
History of stroke or TIA 10 (16.95%) 5 (14.29%) 5 (20.83%) NS
Hypertension 45 (76.27%) 27 (77.14%) 18 (75%) NS
Chronic kidney disease 17 (28.81%) 9 (25.71%) 8 (33.33%) NS
Smoking status
Never 10 (16.95%) 6 (17.14%) 4 (16.67%)
NSFormer 41 (69.49%) 25 (71.43%) 16 (66.66%)
Current 8 (13.56%) 4 (11.43%) 4 (16.67%)
Endovascular 
procedure
PTA 39 (66.1%) 22 (68.57%) 15 (62.5%)
NS
PTA + stenting 20 (33.9%) 11 (31.43%) 9 (37.5%)
TBI of the treated limb was signifi cantly lower in patients with poorly controlled 
diabetes than in patients with HbA1C ≤8.0 both at 6 [0.2 (0.0–0.38) vs. 0.38 
(0.31– 0.46); p <0.008] (Fig. 1) and 12 month follow-up [0.17 (0.0–0.27) vs. 0.32 
(0.25–0.38); p <0.001] (Fig. 2). Lack of improvement of TBI in 12-months compared 
to postoperative TBI was more frequent in HbA1C >8.0 patients than in normal HbA1C 
patients (69.57% vs. 37.5%; p = 0.04). ABI was immeasurable in 57.69% patients with 
poorly controlled diabetes compared to only 27.78% of normal HbA1C patients.
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Fig. 1. Diff erence in toe-brachial index (TBI) between group of patients with HbA1C ≤8.0% and HbA1C 
>8.0% at 6 month follow-up.
Fig. 2. Diff erence in toe-brachial index (TBI) between group of patients with HbA1C ≤8.0% and HbA1C 
>8.0% at 12 month follow-up.
Th ere weren’t signifi cant diff erences in preoperative QoL between both groups of 
patients, as described in Table 2.
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Table 2. Levels of preoperative quality of life assessed by VascuQol and EuroQol-5D questionnaires. In 
VascuQol higher result represents better life quality, but in EuroQol-5D higher results represents worse 
life quality (except VAS).
HbA1C ≤8 HbA1C >8 P
VascuQoL Pre Activity [average (±)] 1.78 (±0.63) 2.02 (±0.95) 0.4703
VascuQoL Pre Symptoms [average (±)] 3 (±1.39) 2.96 (±1.35) 0.8999
VascuQoL Pre Pain [average (±)] 2.66 (±1.7) 2.63 (±1.58) 0.9451
VascuQoL Pre Emotional well-being [average (±)] 2.11 (±0.88) 2.43 (±1.2) 0.4182
VascuQoL Pre Social well-being [average (±)] 2.03 (±1.42) 2.47 (±1.56) 0.3724
EuroQol-5D Mobility [average (±)] 2.47 (±0.62) 2.28 (±0.59) 0.4097
EuroQol-5D Selfcare [average (±)] 1.94 (±0.75) 1.62 (±0.68) 0.1474
EuroQol-5D Daily activities [average (±)] 1.88 (±0.78) 1.96 (±0.79) 0.7363
EuroQol-5D Pain [average (±)] 2.29 (±0.69) 2.28 (±0.65) 0.8997
EuroQol-5D Anxiety [average (±)] 1.65 (±0.79) 1.79 (±0.62) 0.3682
EuroQol-5D VAS [average (±)] 46.47 (±18.35) 51.43 (±15.57) 0.5829
Diff erences in quality of life changes (12-month vs. preoperative) between groups 
were observed in all 5 domains of VascuQol, however only 3 of them were statistically 
signifi cant (symptoms, pain and emotional well-being) (Fig. 3). Results of EQ5D-3L 
presented signifi cant diff erences in QOL changes only in mobility domain (Fig. 4). 
Patients with HbA1C ≤8.0% had signifi cantly higher rate of life quality improvement 
in 4 out of 5 VascuQol-25 domains (activities: 88.2% vs. 53.8%, p = 0.019; symptoms: 
88.2% vs. 50.0%, p = 0.010; emotional well-being: 94.1% vs. 65.4%, p = 0.029; social 
well-being: 82.3% vs. 46.2%, p = 0.018). In pain domain rate of improvement had 
the same tendency however there was no statistical signifi cance (70.6% vs. 42.3%, 
p = 0.069).
Fig. 3. ΔVascuQol-25 in each of 5 domains compared between patients with HbA1C ≤8.0% and HbA1C 
>8.0%. Higher result represents better quality of life in all 5 domains.
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Fig. 4. ΔEuroQol 5D-3L in each of 5 domains and VAS compared between patients with HbA1C ≤8.0% 
and HbA1C >8.0%. Lower result represents better quality of life in all 5 domains. In VAS higher result 
represent better QoL.
Discussion
Results summary
Patients with HbAC1 ≤8.0% have better TBI results in 6 and 12-month observation 
aft er PTA (Fig. 1 and Fig. 2). Th ey also present lower rate of restenosis and higher 
rate of healed ulcerations. Quality of life, especially regarding activities, symptoms, 
emotional well-being and social well-being, improved more frequent and the 
improvement was greater.
Role of glycaemia control in atherosclerosis management
It has been proven in multiple studies that properly controlled glycaemia plays crucial 
role in both short- and long-term outcomes of DM patient’s treatment  [18– 20]. 
In 2019 Guidelines on the management of diabetic patients was stated that HbA1C 
should be kept ≤8.0% “in patients at an advanced age and/or in diabetics with 
macroangiopathic complications […] and/or multiple comorbidities” [17]. Elevated 
HbA1C level is one of the most important factors on atherosclerosis progression and 
trigger factor for its complications [21, 22]. According to Iren Drange Hjellestad et al. 
“HBA1C results may identify persons at high risk of long-term mortality following 
surgical treatment for PAD” [22]. Recent study conducted by Shipra Arya et al. shows 
that elevated preoperative glycaemia in patients undergoing endovascular treatment 
or vascular surgery have higher probability of limb amputation and/or MACEs [23].
Quality of life
Th e aspect of quality of life is oft en overlooked, but it is one of the most 
important outcomes of any treatment, especially in chronic diseases. Following 
other studies design we decided to cover patients with 2 diff erent types of QoL 
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questionnaires  [24– 26]. As the results show, the EQ5D-3L did not gave many 
signifi cant dependences, which is due to its nature — this questionnaire is a generic 
one and may be less useful is small study groups. Vascuqol-25 questionnaire provided 
us with much important information, even if some dependence did not presented 
the statistical signifi cance, they kept the same trend and possibly the signifi cance 
would be stronger if the population was bigger. However one of the negative results 
raised our concern — the rate of patients with improvement in pain domain did not 
signifi cantly diff er between groups. In our opinion this can be explained by the fact 
that patients with DM oft en suff er from diabetic peripheral neuropathy, which may be 
lowering the sense of pain [27]. Our hypothesis is supported by the fact, that patients 
with proper glycaemia who reported improvement in pain feeling showed bigger 
diff erence in this domain compared to those with elevated HbA1C (Fig. 3).
ABI and TBI measurements issues
Although described new methods, ABI as a non-invasive, low-cost measurement 
is one of the most common methods of proper lower limbs blood circulation 
assessment  [28]. Unfortunately it oft en tends to be less accurate in patients suff ering 
from DM due to arteries calcifi cations [29, 30]. Th at is why in this study full analysis 
of ABI measurements was not performed, however rate of ABI immeasurability has 
been checked. Th ere is no objective or standardized defi nition of neither TBI nor ABI 
improvement or worsening. Both of those parameters should be assessed accompanied 
by patients’ symptoms and their general condition. Basing on our experience, for the 
purpose of this study we defi ned the improvement of TBI as Δ ≥10% or Δ <10% but 
within the normal range (TBI ≥0.74) [31].
Clinical outcomes controversies
Our results did not confi rm the higher rate of amputations and MACEs in patients 
with higher preoperative HbA1C described by Shipra Arya et al. [23], which probably 
was caused by low number of those events observed. Diff erence in rate of ulcerations 
healed was signifi cant, but only in 6-month observation and was not present in 1-year 
observation. Th e reason for this phenomena was that patients with unhealing wounds 
and restenosis (whose number was greater in HbA1C >8.0 group) were oft en undergoing 
reinterventions aft er 6-month improving the healing of ulcerations in next months.
Study limitations
Th e main limitation of this study is modest sample size, which were only 59 patients. 
Th e subject of infl uence of increased preoperative HbA1C on long term outcomes 
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aft er endovascular procedures and open vascular surgery have been explored by big 
studies, however the novelty of this study is based on the assessment of quality of life 
changes in patients during 1-year observation [21, 23]. What is more we analyzed 
more homogenic group, as all of patients included in this study were diabetics, 
undertaking insulinotherapy and undergoing only endovascular treatment. To 
perform the complete analysis the confounding factors need to be balanced as well as 
multivariable analysis should be performed. Also calculation of 5 or 10 years survival 
rate would be benefi cial for the study. Another, minor limitation is lack of complete 
data on presence of neuropathy in studied patients. Concluding all those mentioned 
limitations, there is clear need for long-lasting prospective study with larger sample 
size to confi rm our results.
Conclusions
Results of this study show that the level of HbA1C is an important factor of long-term 
prognosis in diabetic patients with critical limb ischemia. Elevated level of HbA1C 
negatively aff ects the life quality improvement in diabetic patients subjected to PTA of 
the lower limbs arteries in long-term observation.
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